12 September 2017

Invest in Skåne

Hosted by: Invest in Skåne

View session Description
Seminar on Drug Development at MAX IV and ESS

Medicon Village, Lund / Guided tour to MAX IV

10:00 - 16:30Bus Tour to Lund

Learn how your company can benefit from the advanced research tools at MAX IV and ESS in your drug development process – from early drug discovery to formulation.

Join a one-day seminar with presentations from MAX IV and ESS as well as companies that are taking advantage of the analytical techniques available at these research facilities. You will get an insight on how these tools create value and how they can help you in developing new drugs of tomorrow.

The day will be rounded off by a guided tour to the MAX IV laboratory. Register here

Detailed agenda:

Moderator: Pia Kinhult, Strategic Advisor, ESS
10:00 – 10:30  Bus takes participants from Malmömässan to Medicon Village
10:30-11:00 Registration and Coffee
11:00-11:10 Welcome to Medicon Valley
Stefan Johansson, Managing Director at Invest in Skåne
11:10-11:30 Industrial usage of ESS
Sindra Petersson Årsköld, Senior Advisor, ESS
11:30-11:50 Industrial usage of MAX IV
Tomas Lundqvist, Life Science Director, MAX IV
11:50-13:00 LUNCH
13:00-13:20 Fragment-based drug discovery
Björn Walse, CEO at SARomics Biostructures
13:20-13:40 Protein drug development – application of small angle scattering methods
Mathias Norrman, Principle  Scientist at Novo Nordisk
13:40-14:00 MAX IV and ESS in future drug development – from an Astra Zeneca perspective
Anna Collén, Senior Project Director in Pharmaceutical Sciences, Astra Zeneca
14:00-14:15 Summary
14:15-15:45 Bus to MAX IV for a guided tour
16:00-16:40 Bus from MAX IV to Malmö Mässan – the conference venue
The Address to Medicon Village is – Scheelevägen 2, 223 63 Lund.

Moderator: Pia Kinhult - Strategic Advisor - ESS

Pia Kinhult - Strategic Advisor - ESS Stefan Johansson - Managing Director - Invest in Skåne Sindra Petersson Årsköld - Senior Advisor - ESS Tomas Lundqvist - Life Science Director - MAX IV Björn Walse - CEO - SARomics Biostructures Mathias Norrman - Principle Scientist - Novo Nordisk Anna Collén - Project Director Pharmaceutical Development - AstraZeneca


Hosted by: AbbVie

View session Description

Academic Catwalk

17:00 - 18:15Main Hall

Nordic academic scientists will showcase intriguing research that could be the base for next generation therapies. The presentation will be followed by a short Q&A and is intended to give rise to inspiring discussions.

SmiLe Incubator
Johnson & Johnson Innovation

Hosted by: SmiLe IncubatorCo - Hosted by: Johnson & Johnson Innovation

View session Description

Startup Challenge @ NLSDays

18:30 - 20:00Main Hall

The Startup Challenge is a pitching competition giving innovative entrepreneurs an opportunity to showcase. Selected companies will present their innovative technologies to a selected jury representing life science executives from industry and finance.

Confirmed companies:

Optimov (DEN) – Metabogen (SWE) – Bactavia (SWE) – Innovosens (SWE) – Sidekick Health (SWE) – Saga Diagnostics (SWE) – Neosense (SWE) – Adesante (FIN) – Cerenion (FIN) – Lipigon (SWE) – Immuneed (SWE) – Scandicure (SWE) – Edvince (SWE) – Finn Medicinen (SWE)

Jury Members:

Rosemary Liu – Healthcare Solution Lead – Johnson & Johnson Innovation

Sandra Lindvall – Associate – Awapatent

Tomas Eriksson – CEO – A1M Pharma

13 September 2017


Hosted by: SwedenBIOCo - Hosted by: bionordic

Olivier Duchamp - Managing Director - NLSDays, CEO - Bionordic Services Jonas Ekstrand - Managing Director - SwedenBIO Mikael Dolsten - President Worldwide Research and Development and EVP - Pfizer


09:30 AstraZeneca - Pharmaceutical 09:50 Pfizer - Pharmaceutical 10:10 Boehringer Ingelheim - Pharmaceutical 10:30 Johnson & Johnson Innovation - Pharmaceutical


09:30 Affilogic - Biotechnology - Other 09:37 Cline Scientific - Biotechnology - Other 09:49 Disruptive Materials - Biotechnology - Other 10:01 Axenis - Biotechnology - R&D Services 10:08 Bertin Pharma - Biotechnology - Therapeutics & Diagnostics 10:15 Cardiabase - Biotechnology - R&D Services 10:22 Neurotar - Biotechnology - R&D Services 10:34 BerGenBio - Biotechnology - Therapeutics & Diagnostics 10:41 Immunicun - Biotechnology - Therapeutics & Diagnostics

Lund University Diabetes Center
LU Innovation
Novo Nordisk

Hosted by: Lund University Diabetes CenterCo - Hosted by: LU Innovation, Novo Nordisk, Sanofi, Medeon

View session Description
Game changers in diabetis treatment

Super Session 1 – Diabetes

09:30 - 10:45Plenary Room - Main Hall

The diabetes session will focus on disruptive new solutions and future diabetes treatment options. Special focus will be on recent developments , where closed loop systems and ultrafast acting insulins will be game changers for insulin treated diabetes patients, especially those with unstable blood glucose.

Moderator: Karin Hehenberger - CEO and Founder - Lyfebulb

Søren Bregenholt - Corporate VP and Head of External Innovation - Novo Nordisk Charlotte Ling - Professor, Lund University Uli Wendt - Head External Innovation and Alliance Management, Global Diabetes Division, R&D - Sanofi Karin Hehenberger - CEO and Founder - Lyfebulb


11:15 Catalyze - CRO/CMO 11:27 Covance - CRO/CMO 11:39 Particle Analytical - CRO/CMO 11:51 Recipharm - CRO/CMO 12:03 VivoPharm - CRO/CMO 12:15 Cilcare - CRO/CMO 12:22 Pharm-Analyt Labor - CRO/CMO

Invest Stockholm

Hosted by: Invest Stockholm


11:15 Abera Bioscience - Biotechnology - Therapeutics & Diagnostics 11:22 Pelago Bioscience - Biotechnology - R&D Services 11:29 Double Bond Pharmaceutical - Pharmaceutical 11:35 Eurocine Vaccines - Biotechnology - Therapeutics & Diagnostics 11:42 Gradientech - Biotechnology - Therapeutics & Diagnostics 11:49 Scandinavian Biopharma - Biotechnology - Therapeutics & Diagnostics 11:56 Sinsa Lab - Biotechnology - Therapeutics & Diagnostics 12:03 Q-Linea - Biotechnology - Therapeutics & Diagnostics 12:10 NeoDynamics - HealthTech 12:17 Diamyd Medical - Biotechnology - Therapeutics & Diagnostics

Business Region Göteborg
Invest in Skåne

Hosted by: Business Region GöteborgCo - Hosted by: Invest in Skåne

View session Description
Gene therapy in regenerative medicine

Super Session 2 – Regenerative Medicine

11:15 - 12:30Plenary Room - Main Hall

This supersession will focus on a specific field of regenerative medicine, Gene Therapy. The possibility to replace defective genes in a patient’s cells with healthy ones using viral vectors and gene editing technologies, opens up the potential to treat or prevent numerous diseases which currently lack successful treatment. Although most gene therapies are still in an experimental stage, several examples have recently been successfully translated into clinical practice and products with regulatory approval. This session will discuss the diverse challenges involved in the translation of gene therapies to clinic and market, and highlight some successful examples.

Steffen Thirstrup - Director Regulatory Advisory Board - NDA Reg Benjamin Schmid - Research Scientist, Disease Models - Bioneer Sven Kili - Head of Cell & Gene Therapy Development - GSK Ralf Knöll - Chief Scientist - AstraZeneca

Anders Hjelmencrantz - Partner and European Patent Attorney - Zacco Ana Maria Henao Restrepo - Medical Officer, Department of Immunization Vaccines and Biologicals - WHO Guiseppe Ciaramella - Chief Scientific Officer - Moderna Valera Therapeutics Agnete Fredriksen - Chief Scientific Officer - Vaccibody AS

14:00 Biotrial Research - CRO/CMO 14:07 Clean Cells - CRO/CMO 14:14 PQE - Professional Services & Consulting 14:21 Amplexor - Professional Services & Consulting 14:28 RiverArk - Professional Services & Consulting 14:40 IntraVacc - Public & Non-Profit Organization 14:47 Rise Acreo - Public & Non-Profit Organizations 14:59 Asahi Kasei Bioprocess - Supplier & Engineering


Hosted by: Vinnova

Sara Gunnerås - Director EU Support Office - SwedenBIO Elisabet Nielsen - EUREKA National Project Coordinator - Vinnova Inga Bruskeland - National Project Coordinator - Research Council of Norway Peter Lindberg - EUROSTARS Program Manager - Vinnova

Arthur D. Little

Hosted by: DNBCo - Hosted by: Arthur D. Little

View session Description
A new mechanism to fund excess Clinical Stage projects

Super Session 4 – Financing of Phase 3 Studies

15:45 - 17:00Plenary Room - Main Hall

Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed – resulting in decline of asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaboration with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. There are several potential advantages of this approach. But this session will also reflect upon questions like: What would be the primary driving forces for different parties to engage in this type of collaborations? Are there also complications with the phenomenon? How does the excess of promising assets with large biopharma companies affect other parts of the life science ecosystem?

Moderator: Ulrica Sehlstedt - Partner - Arthur D. Little

Jo Sawyer - Head of External Partnerships - Novartis Ben van der Schaaf - Principal - Arthur D. Little Ulrica Sehlstedt - Partner - Arthur D. Little Johan Christenson - Partner - HealthCap Birgitte Volck - Vice President, Head of R&D Rare Diseases - GSK

15:45 AbbVie - Pharmaceutical 16:05 Bayer - Pharmaceutical 16:25 Bristol-Myers Squibb - Pharmaceutical 16:45 Beactica - Biotechnology - Therapeutics & Diagnostics

Potter Clarkson

Hosted by: Potter Clarkson

Mats Grahn - CEO - Immunovia Olivier Laing - Senior Associate, IP Solicitor - Potter Clarkson Steve Smith - European Patent Attorney - Potter Clarkson

View session Description

Official Networking Reception at Copenhagen Papirhallen

18:00 - 22:00Copenhagen - Papirhallen

Papirhallen is an old paper warehouse in Copenhagen, updated with respect for the old and original look, offering unique atmosphere for creating a great networking experience.

14 September 2017


Hosted by: SwedenBIOCo - Hosted by: Covance

View session Description
Value creation in service providers

Super Session 5 – Preclinical & Clinical Methodological Advancements

08:00 - 09:15Plenary Room - Main Hall

Many of the service providers in life science R&D have their own research. They provide much more than just an extra pair of hands and they spend high amounts on in house development of their services. With this super session, we will highlight their efforts and importance for the life science ecosystem where many of the companies are small and source for the latest technologies for their research and development.

Moderator: Christina Herder - CEO - Modus Therapeutics

Christina Herder - CEO - Modus Therapeutics Torkel Gren - Senior Sales Director, Development Services - Recipharm Sverre Bengtsson - CEO - Pharma Consulting Group Andy Gibbs - Drug Development Leader - Covance Michael Dabrowski - CEO - Pelago Bioscience

08:00 OxThera - Biotechnology - Therapeutics & Diagnostics 08:12 Spago Nanomedical - Biotechnology - Therapeutics & Diagnostics 08:24 Staten Serum Institut - Biotechnology - Therapeutics & Diagnostics 08:36 Stayble Therapeutics - Biotechnology - Therapeutics & Diagnostics 08:48 Thermo Fisher Scientific - Biotechnology - Therapeutics & Diagnostics 09:00 Wnt Research - Biotechnology - Therapeutics & Diagnostics


08:00 Targovax - Biotechnology - Therapeutics & Diagnostics 08:07 Acesion Pharma - Biotechnology - Therapeutics & Diagnostics 08:19 Hansa Medical - Biotechnology - Therapeutics & Diagnostics 08:31 Oncology Venture - Biotechnology - Therapeutics & Diagnostics 08:43 Ectin Research - Pharmaceutical 08:50 Klaria Pharma - Pharmaceutical 08:57 Redwood Pharma - Pharmaceutical 09:04 Vicore Pharma - Pharmaceutical

Bristol-Myers Squibb

Hosted by: AbbVieCo - Hosted by: Bristol-Myers Squibb

Moderator: Marianne Larsson - Innovation Director - Innovation Skåne

Amir Hefni - Country Manager - Bristol-Myers Squibb Marianne Larsson - Innovation Director - Innovation Skåne

09:30 Novo Nordisk - Pharmaceutical 09:50 Roche - Pharmaceutical 10:10 Sanofi - Pharmaceutical 10:30 MSD - Pharmaceutical

Danish Agency for Science and Higher Education

Hosted by: VinnovaCo - Hosted by: Danish Agency for Science and Higher Education

View session Description
The innovative Medicines Initiative: speeding up medicines development through open research collaboration with the pharmaceutical industry

Workshop 3 – Innovative Medicine Initiative

09:30 - 10:45Room E

Research collaboration and funding opportunities for SMEs, Research Institutions, Hospitals and other stakeholders in the area of medicine development.

The Innovative Medicines Initiative (IMI2) is Europe’s largest public-private partnership in life science. It is jointly run and funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve the process of developing new drugs and treatments by supporting cooperation in research and development. IMI projects address such themes as preclinical and clinical methodological advancements, Digital Health, personalized medicine, Diabetes, Neurosciences and Oncology

The event is organized by VINNOVA , the Danish Agency for Science and Higher Education and The Research Council of Norway.

Who should join this session?
The workshop is an opportunity for a wide range of stakeholders – not least small and medium sized companies – to learn about the opportunities for R&D collaboration with the European pharmaceutical industry through IMI funded projects.  The workshop will highlight the experiences and learnings of Swedish and Danish IMI project participants from both industry and academia.


  • Welcome
  • Why IMI matters to Europe’s pharmaceutical industry
  • Advancing medicines development through open collaboration on research
  • Joining IMI – the SME  perspective
  • Joining IMI – The academic experience
  • Closing remarks

Magda Chlebus - Director of Science Policy - EFPIA Magali Poinot - Advisor and Legal Manager - IMI Joint Undertaking Peter Olofsson - CEO - Redoxis AB Poul Henning Jensen - Professor - Dept. Of Biomedicine, Aarhus University

Oslo Cancer Cluster

Hosted by: Oslo Cancer ClusterCo - Hosted by: DNB

View session Description
Advancing Cancer Immunotherapy by novel partnerships, bugs and bytes

Super Session 7 – Transformative Oncology

11:15 - 12:30Plenary Room - Main Hall

The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.

Moderator: Benedicte Bakke - Senior Advisor, International Healthcare - DNB

Benedicte Bakke - Senior Advisor, International Healthcare - DNB Khatereh Ahmadi - Executive Director, Oncology Search and Evaluation Lead - MSD Per Norlèn - CEO -Alligator Bioscience Stefan Ries - Global Head of External Innovation, Oncology Discovery - pRED Roche Christophe Bonny - CSO - Enterome Henrik Winther - Senior Vice President, Precision Diagnostics - Immunovia Richard Stratford - CEO - OncoImmunity Gary Sclar - Vice President - Dana-Farber Innovations

11:15 Cadila Pharmaceuticals Sweden AB - Pharmaceutical 11:27 Camurus - Biotechnology - Therapeutics & Diagnostics 11:39 Daiichi Sankyo - Pharmaceutical 11:51 Index Pharmaceuticals - Pharmaceutical 12:11 Nexstim - MedTech 12:18 Medicollect - CRO/CMO

Invest in Skåne

Hosted by: Invest in Skåne

View session Description
The Future of Drug Formulation using MAX IV & ESS

Workshop 4 – ESS & MAX IV

11:15 - 12:30Room E

How can your company benefit from using MAX IV and ESS when developing new drug formulations?

The pharmaceutical industry will give examples on how they have used synchrotron and neutron light sources in drug formulation experiments and what potential they see with these facilities in the future.

Moderator: Anna Sandström - Director Science Relations - AstraZeneca

Anna Sandström - Director Science Relations - AstraZeneca Anna Collén - Project Director Pharmaceutical Development - AstraZeneca Mathias Norrman - Principle Scientist - Novo Nordisk

PRV Swedish Patent and Registration Office

Hosted by: NovoCo - Hosted by: Industrifonden, Nasdaq, PRV Swedish Patent and Registration Office

Moderator: Pontus Ottosson - Head of Investments - Chalmers Ventures

Pontus Ottosson - Head of Investments - Chalmers Ventures Anna Danestig - Key Account Manager - PRV Yilmaz Mahshid - Investment Manager Life Science - Industrifonden Stephan Christgau - Partner - Novo Seeds

Arthur D. Little

Hosted by: bionordicCo - Hosted by: SwedenBIO, Arthur D. Little

Nils Bohlin - Partner & Global Leader Healthcare - Arthur D. Little Jonas Ekstrand - Managing Director - SwedenBIO Olivier Duchamp - Managing Director - NLSDays, CEO - Bionordic Services